Semaglutide 10mg Vial

Overview

Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1 (GLP-1). It is a long-acting GLP-1 receptor agonist developed for the treatment of metabolic disorders.

Semaglutide has received regulatory approval in multiple regions for type 2 diabetes management and chronic weight management, depending on formulation and indication.

Mechanism of Action

Semaglutide activates GLP-1 receptors, which:

• Enhance glucose-dependent insulin secretion

• Suppress inappropriate glucagon release

• Slow gastric emptying

• Promote satiety and reduce appetite

• Improve glycemic control

Unlike dual or triple agonists, semaglutide works solely through GLP-1 receptor activation and does not activate glucagon or GIP receptors.

Its extended half-life (~1 week for injectable forms) is achieved through structural modifications that increase albumin binding and resistance to enzymatic degradation, allowing for once-weekly dosing (in injectable form).

Research & Clinical Use Areas

Semaglutide has been studied extensively in large clinical trial programs (e.g., SUSTAIN, STEP, PIONEER) for:

• Type 2 diabetes

• Obesity and overweight management

• Cardiovascular risk reduction

• Metabolic syndrome

Clinical trials have demonstrated:

• Significant HbA1c reduction

• Substantial body weight reduction

• Cardiovascular outcome benefits in high-risk patients

Key Differences vs Dual/Triple Agonists

Compared to dual agonists (like GLP-1/glucagon or GLP-1/GIP compounds), semaglutide:

• Focuses primarily on appetite suppression

• Has strong glycemic control data

• Does not directly increase energy expenditure via glucagon receptor activation

This makes it highly effective for weight reduction primarily through reduced caloric intake rather than metabolic rate elevation.

FOR RESEARCH USE ONLY